Bayer announced today that the FDA has accepted their new drug application (NDA) for menopause drug, elinzanetant, to treat ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Studies measuring patient preference stacked up in subcutaneous administration’s favor, according to a recently published ...

The higher dose led to a more rapid decline in an important marker of neurodegeneration, according to a Biogen news release ...

The results showed that 26% of patients who received tulisokibart achieved clinical remission at week 12 compared with 1% of ...

As the global population ages, respiratory viral infections have become a significant health concern, leading to severe ...